Introduction
============

Studies have shown that in adult bone marrow and circulating blood there is a population of cells similar to embryonic angioblasts, known as endothelial progenitor cells (EPCs). These cells are types of stem/progenitor cells with the potential to differentiate into mature endothelial cells and to settle among injured vascular endothelial cells in order to repair damaged blood vessels. In humans, EPCs have been characterized as CD133, CD34, and VEGFR2 (KDR) positive cells [@B1]-[@B4].

The identification of EPCs in adult bone marrow and circulating blood, revised the dogma on adult vascularization from one in which angiogenesis was the only process active in adult vascularization. This earlier concept speculates that circulating endothelial cells (CECs) which had emerged from existing endothelial structures contribute to formation of distant vascular structures. A newer construct proposes that this process, now identified as postnatal vasculogenesis, is a type of adult neovascularization, dependent on bone marrow derived EPCs [@B1], [@B5]**.**In contrast with endothelial cells, EPCs have a much stronger ability to proliferate and to contribute to angiogenesis [@B6], [@B7]. Accumulated evidence has shown the importance of EPCs for neovascluraization and vascular remodeling [@B8], [@B9]**.** EPCs have been used in the treatment of vascular diseases [@B10], promoting reconstruction of ischemic region [@B11], and have recently played an important role in regeneration medicine [@B12], [@B13]. Nonetheless, the limited availability of EPCs is still a bottle neck that restricts their broad application in regenerative medicine.

One of the important potential sources of EPCs is from the differentiation of embryonic stem cells. Studies have demonstrated that endothelial cells (ECs) and smooth muscle cells (SMCs) are both separate cell lineages derived from human embryonic stem cells [@B14]-[@B16]. Human embryonic stem cell-derived EPCs and smooth muscle progenitor cells (SMPCs) are capable of endothelial and smooth muscle cell function. This research has defined the developmental origin and revealed the relationship between these two cell types and provides a complete biological characterization. The discovery that forced expression of the four transcription factors OCT4, Sox2, Klf4, and c-Myc is sufficient to confer a pluripotent state upon the murine and human fibroblast genome, generating induced pluripotent stem cells (iPSCs). These cells have properties similar to embryonic stem cells (ESCs) with regard to their multilineage differentiation potential *in vitro* and in vivo [@B17], [@B18]. The discovery of iPSCs resolved the ethical issues which has plagued the application of ESCs in regenerative medicine. Since then, the rapid progress has been made in the studies on the ways to generate iPSCs from various somatic cells with the defined factors, including skin fibroblasts [@B18], [@B19], keratinocytes [@B20], endothelial cells [@B21], and blood progenitor cells [@B22]. For example, Yin L. et al by partially reprogramming rat endothelial cells with the same four transcription factors originally described by Yamanaka [@B17] forced their expression in rat aorta endothelial cells to successfully generate induced vascular progenitor cells (iVPCs) [@B23]. These cells remained committed to vascular lineage and could differentiate into vascular ECs and vascular smooth muscle cells (VSMCs) via EPCs and SMPCs *in vitro* [@B23]. These cells were demonstrated better *in vitro* angiogenic potential than native ECs [@B23].

To decrease the risk of teratoma formation, great efforts have been made to generate iPSCs by decreasing the number of factors used. In this respect**,**octamer binding transcription factor 4 (OCT4), also known as POU domain, class 5, transcription factor 1 (POU5F1) alone has been successfully used to generate iPSCs from human fetal neural stem cell [@B24]. OCT4 has also been found to be essential for the maintenance stem-ness of embryonic stem cells [@B25] and its expression is normally confined to pluripotent cells of embryos [@B26]. However, research on whether OCT4 alone might induce human EPCs from ECs has not been reported. Based on the evidence described above the present studies were carried out to explore whether forced expression of OCT4 might generate EPCs from HUVECs and, if so, to elucidate the possible mechanism involved.

Materials and Methods
=====================

Materials
---------

HUVECs and endothelial cell medium (ECM) were from the ScienCell Research Laboratories (San Diego, USA). Doxycycline (DOX) was purchased from Sigma (St. Louis, USA). Fetal bovine serum (FBS) was from HyClone Inc. (Logan, USA). The Lentiviral Packaging Kit was purchased from Biowit Tech. (Shenzhen, China). The plasmids FUW-M2rtTA and TetO-FUW-OCT4 were from Addgene (Cambridge, USA). *In Vitro* Angiogenesis Assay Kit was from Millipore (Billerica, USA). Calcein-AM was purchased from Santa Cruz Biotechnology, Inc. (Dallas, USA). PCR primers were synthesized from Sangon Biotec. (Shanghai, China). Trizol Reagent, RT-reaction Kit, and SYBR® Green PCR Master Mix were purchased from TaKaRa Biotec. (Dalian, China).

Cell culture and treatments
---------------------------

The HUVECs were grown in ECM medium containing 5% FBS and 1% endothelial cell growth supplement (ECGS) at 37°C in 5% CO~2~and humidified atmosphere. Cells were used for all experiments at passages 2 to 6. For OCT4 induction, the cells were plated in dishes of a 6 cm diameter at a density of 0.5 × 10^6^ cells per dish. After incubating them for 24 hours, the medium was exchanged with fresh medium containing DOX (2 µg/ml) or vehicle and was changed every other day until 7 days when all the cells were harvested.

Transduction of HUVECs
----------------------

The plasmids FUW-M2rtTA and TetO-FUW-OCT4 were purified with an Endo-Free Plasmid Mini Kit (OMEGA, Norcross, USA). The pseudo-virus packaging was performed by using lentiviral packaging kit according to manufacturer\'s instruction in 293-T cells. The supernatants were collected at 48h and 72h after transfection and the pseudo-virus were concentrated by high-speed centrifugation (50000g for 2 hour at 4°C). HUVECs were transduced by using the pseudo-virus and polybrene (4μg/ml) for 24 hours. The medium was changed on the second day.

RNA purification and RT-QPCR
----------------------------

Total RNA from the cells was purified with a TRIzol Reagent following the manufacturer\'s instruction. The purity and quantity of the RNA was measured with spectrophotometer and the quality of RNA was further monitored by agarose gel electrophoresis. After treatment with RNase-free DNase I, RNA was subjected to reverse transcription with a RT-reaction Kit. The cDNA product was amplified and quantified with 7300 Real-time PCR system (Applied Biosystems) in a 25 μl reaction volume using SYBR® Green PCR Master Mix. The primer sets used for PCR amplification are shown in Table [1](#T1){ref-type="table"}. The thermal cycling program consisted of 2 min at 50°C, 10 min at 95°C, followed by 40 cycles for 15 sec at 95°C and 1 min at 60°C. After amplification, a melting curve was generated and data analysis was performed by using Dissociation Curves 1.0 software (Applied Biosystems). The normalized value was given by the ratio of mRNA of the target gene to mRNA of the reference gene (RPL13A) in each sample. Fold activation was given by the ratio of the normalized values of the cells incubated with (+DOX) to that without (-DOX) DOX.

In vitro angiogenesis assay
---------------------------

The angiogenesis of the cells was evaluated by a Matrigel *in vitro* angiogenesis assay technique [@B27], [@B28]. Briefly, 100μl stock solution of Matrigel was added to each well in 48-well plates and kept at 37°C for 30 min in order to form the Matrigel. Cell suspensions containing 3×10^4^ cells in 100μl of ECM were seeded on the Matrigel of each well, and incubated for 6 hours. Then Calcein-AM (0.1 mM) was directly added to each well for 20 min at 37°C to stain the cells and imaged under a phase contrast microscope with an excitation wavelength of 490 nm and an emission wavelength of 515 nm. For quantification, the values for the pattern recognition**,**branch point and total capillary tube length were determined following the manufacturer\'s guidelines (ECM625; Millipore). ImageJ software was used in the first instance prior to double-checking by an independent assessor. 5 random microscopic (×100) fields per well were included and the data are expressed as Mean±SD of 5 samples.

Gene expression profiling analysis
----------------------------------

Whole-genome expression arrays were performed by using Roche NimbleGen chips (KangChen, Shanghai, China), an oligonucleotide-probe-based gene array chip containing 45,033 transcripts, which provides a comprehensive coverage of the whole human genome. Total RNA from each sample was isolated and quantified by the NanoDrop ND-1000. The integrity of RNA was assessed by standard denaturing agarose gel electrophoresis. Total RNA was used to synthesize cDNA by reverse transcription reaction, subsequently, which was labeled with a NimbleGen one-color DNA labeling kit, and then Hybridized using NimbleGen Hybridization System following the manufacturer\'s instruction. The chip was washed, and scanned with Axon GenePix 4000B. Following normalization, all files of gene expression level were imported into Agilent GeneSpring GX software (version 11.5) for further analysis. Genes that have values greater than or equal to lower cut-off: 100.0 were chosen for differentially expressed gene screening. After data filtering, scatter plot analysis was performed to assess gene expression data. The values of X and Y axes in the Scatter-Plot are the averaged normalized signal values of each group (log2 scaled). The green lines are Fold Change Lines (The default fold change value given was 2.0).

Bioinformatics analysis
-----------------------

Gene Ontology (GO) [@B29] is a functional analysis to interrogate the possible functions associated with the differentially expressed genes. Following data filtering based on the statistical standard, differentially expressed genes were included in the analysis. The p-value denotes the significance of GO Term enrichment in the differentially expressed gene list. The lower the p-value, the more significant the GO term is. FDR stands for the false discovery rate of the GO item. The lower the FDR value, the less the false discovery rate of the GO item is [@B29].

Statistical analysis
--------------------

All calculations and statistical analyses were performed by using GraphPad Prism 5.0 software (San Diego, CA, USA). T test was used to analyze the significance of any differences between two groups. The statistical significance was defined as *p\<0.05*.

Results
=======

Induced expression of OCT4 in HUVECs
------------------------------------

HUVECs that were lentivirally transduced with the Tet-on controlled OCT4 expression vector were incubated in the presence of DOX or vehicle to induce OCT4 expression in the cells. OCT4 mRNA was analyzed by RT-QPCR. The results are shown in Fig. [1](#F1){ref-type="fig"}. OCT4 mRNA was increased by more than 20 fold in the cells treated with DOX, when compared with the cells not exposed to DOX. These results indicate that the cellular model for DOX induced OCT4 expression was established.

OCT4 enhanced the angiogenesis of HUVECs
----------------------------------------

Angiogenesis is the major function of vascular endothelial cells (ECs) and their precursor, endothelial progenitor cells (EPCs), which have a potential application for cell therapy because they have a much stronger ability for angiogenesis, when compared with mature ECs [@B6], [@B7]. To determine whether OCT4 can enhance the angiogenesis of HUVECs or not, an *in vitro* angiogenesis assay system was used to evaluate the changes of*in vitro* angiogenesis of the cells, based on the formation of tubular networks. The angiogenesis assay was performed for HUVECs which were lentivirally transduced with the Tet-on controlled OCT4 expression vector and incubated with or without Tet-on inducer DOX. The results are shown in Fig. [2](#F2){ref-type="fig"}, in which A and B are representative microscopic appearances and C-E where the results are statistically analyzed. Clearly, more tubular networks were formed in the cells induced with DOX (+DOX) and a lower percentage of network formations was found in un-induced cells (-DOX). These results indicate that forced expression of OCT4 enhanced angiogenesis of HUVECs, suggesting that OCT4 might remodel the phenotype of the cells from ECs to EPCs.

OCT4 altered gene expression profiles in HUVECs
-----------------------------------------------

To explore the molecular mechanism, underlying the finding that forced expression of OCT4 enhanced angiogenesis of HUVECs, whole genome expression arrays were carried out in HUVECs lentivirally transduced with the Tet-on controlled OCT4 expression vector and incubated in the presence of DOX or vehicle. The Scatter-Plot analysis of the changes in the gene expression profile was made to show the global change of gene expression profile in HUVECs induced by DOX. This is shown in Fig. [3](#F3){ref-type="fig"}. Each point on the scatter plot represents the expression level of an individual mRNA, as determined by units of fluorescence intensity. The values of X and Y axes of each point in the Scatter-Plot represent the levels of respective mRNA of the cells treated with (+DOX in Fig. [3](#F3){ref-type="fig"}) and without DOX (-DOX in Fig. [3](#F3){ref-type="fig"}), respectively. The default fold change value given is 2.0 (within the range of green lines). The points above the top and below the bottom green lines represent the genes whose mRNA changed more than 2 fold between two groups of cells. The numbers of genes whose expression was up-regulated were 530 genes over 2 fold, 44 genes over 5 fold and 19 genes over 10 fold. In contrast, the numbers of genes whose expression was down-regulated were 502 genes over 2 fold, 68 genes over 5 fold and 20 genes over 10 folds. The results indicate that the expression of OCT4 broadly changed the gene expression profile of HUVECs.

To focus on the genes whose expression was extremely altered by OCT4, the 20 most up-regulated and down-regulated mRNAs were identified and are shown in Table [2](#T2){ref-type="table"} and Table [3](#T3){ref-type="table"}, respectively. Table [2](#T2){ref-type="table"} lists the 20 mRNAs that were most up-regulated by induction of OCT4 in HUVECs**.**Most of these mRNAs were increased by more than 10 fold in magnitude (with the exception of only one mRNA which was increased by more than 9 fold). Interestingly, OCT4 mRNAs (POU5F1 in Table [2](#T2){ref-type="table"}) and the other three mRNAs (CD133, CD34, and VEGFR2) were among them. OCT4 is a transcription factor of stem cells and maintains the stem-ness of the cells by a series of complex regulated positive feedback networks. Increased expression of human OCT4 mRNAs indicates that the induction of ectopic mouse OCT4 can initiate the transcription of the endogenous human OCT4 gene, whose transcript is undetectable in HUVECs. CD133, CD34, and VEGFR2 have been accepted, as three molecular markers of human EPCs [@B1]-[@B4]**.** The results suggest that the forced expression of OCT4 can remodel the phenotype of HUVECs from ECs to EPCs. Table [3](#T3){ref-type="table"} lists the 20 mRNAs that were most down-regulated by OCT4 in HUVECs. Most of them, with the exception of two mRNAs, were decreased more than 5 fold in the magnitude.

To validate the alteration of mRNAs by OCT4 in HUVECs, expression of thirteen of the mRNAs was further confirmed by RT-QPCR. These were chosen based on five of the mRNAs which were up-regulated over tenfold: AVIL (85.2), OCT4 (14.1), KDR (15.8), CD34 (13.2), CD133 (11.0); and eight of down-regulated: S100A4 (0.14), SLC12A3 (0.16), S100P (0.08), FOLR1 (0.11), IQCF1 (0.24), CD31 (0.36), VE-Cadherin (0.15) and vW-Factor (0.60). These all demonstrated either more than tenfold changes in expression or are molecular marker of HUVECs. As shown in Table [4](#T4){ref-type="table"}, all of the 13 mRNAs were analyzed showed the same pattern of change in expression by the two techniques. Our results indicate the reliability of the Microarray results. Particularly, we want to point out that human OCT4 and three molecular markers for EPCs, CD133, CD34, and VEGFR2 (KDR), were among the mRNAs whose expressions were highly increased upon treatment with DOX determined by two techniques. The results support above conclusion that phenotypic remodeling of the cells from ECs to EPCs might occur by forced expression of OCT4. The two methods also showed that the mRNAs CD31, vascular endothelial cadherin (VE-cadherin) and von Willebrand Factor (vW-Factor), which are the molecular markers for mature endothelial cells, but not expressed in their progenitor cells, were decreased upon DOX treatment. This result provided additional evidence to support our conclusion.

Cellular functions of the mRNAs regulated by OCT4 in HUVECs
-----------------------------------------------------------

The cellular functions that were targeted by the mRNAs altered by OCT4 were analyzed with Gene Ontology (GO) [@B29]. Interestingly, stem cell maintenance and cell differentiation were among the top functions targeted by up-regulated and down-regulated mRNAs upon OCT4 treatment, respectively, as shown in Table [5](#T5){ref-type="table"}. These results support the argument that OCT4 remodels the phenotype of HUVECs from ECs to EPCs via up-regulating the genes responsible for stem cell maintenance and down-regulating the genes for cell differentiation. Other biological categories of statistical significance targeted by up-regulated mRNAs upon the expression of OCT4 include the apoptotic signaling pathway, defense response, and positive regulation of cellular and biological process. The biological categories targeted by down-regulated mRNAs include the development related (tissue development; system development; and anatomical structure development), cell adhesion and cell-cell signaling. These results gave an additive evidence to support the hypothesis that phenotypic remodeling of the cells from ECs to EPCs might occur by forced expression of OCT4.

Discussion
==========

The limited availability of qualified EPCs is a major concern in regenerative medicine. In the present study, we found that forced expression of OCT4 in HUVECs significantly enhanced the *in vitro* angiogenesis of the cells. It has been reported that EPCs have much better ability for *in vitro* angiogenesis than ECs [@B6], [@B7]. Based on the major role of OCT4 in maintaining stem-ness of embryonic stem cells [@B25] and inducing generation of iPSCs from human fetal neural stem cell [@B24] these results suggest that OCT4 can remodel the phenotype of HUVECs from ECs to EPCs.

Gene expression profile determines the characteristic phenotype and the function of the cells. In the present study, we found that forced expression of ectopic mouse OCT4 broadly changed the gene expression profile of HUVECs. Particularly, it increased the expression of endogenous human OCT4 gene which is a transcription factor of stem cells and plays an important role in keeping the stem-ness of the cells. Its transcript is undetectable in differentiated HUVECs [@B30], [@B31], suggesting that phenotypic remodeling of the cells from ECs to EPCs might occur by forced expression of OCT4 alone in HUVECs. Interestingly, the expression of CD133, CD34, and VEGFR2 which have been accepted as characteristic molecular markers for human EPCs [@B1]-[@B4] significantly increased by the forced expression of OCT4 alone in the HUVECs. The expression of CD31, VE-cadherin and vW-Factor, which are the molecular markers for mature ECs, but not expressed in their progenitor cells [@B32], [@B33], were significantly decreased upon the expression of OCT4. This result supports the argument that forced expression of OCT4 alone remodels the phenotype of HUVECs from ECs to EPCs.

To explore the molecular mechanism on how the expression of OCT4 affects angiogenesis of HUVECs, our special attention has been paid to the genes, whose upregulation might be involved in angiogenesis, upregulated by OCT4 found in this study. In addition VEGFR2 (KDR in Table [2](#T2){ref-type="table"}), whose expression was upregulated about 16 times, the expression of VEGFA, bFGF, eNOS, IL1B and IL6 was also increased significantly upon forced expression of OCT4, although they are not among the top 20 genes. Particularly, VEGFA is among them. It has been reported that VEGF signalling through VEGFR2 is the major angiogenic pathway, and blockage of VEGF/VEGFR2 signalling is the first anti-angiogenic strategy for cancer therapy [@B34]. It seems to us that increased angiogenesis of HUVECs upon OCT4 expression might be attributed to the upregulation of VEGFA and VEGFR2, although further study is required for the exact mechanism involved. In our knowledge, the upregulation of VEGF/VEGFR2 by OCT4 has not been reported in the cells.

Furthermore, by analyzing the cellular functions targeted by the altered mRNAs, stem cell maintenance and cell differentiation were among the top categories targeted by up-regulated and down-regulated mRNAs following forced expression of OCT4. These results further support the argument that OCT4 can remodel the phenotype of HUVECs from ECs to EPCs via up-regulating the expression of genes responsible for stem cell maintenance and down-regulating the expression of genes for cell differentiation. The results provide additive evidence supporting the hypothesis that the forced expression OCT4 alone in HUVECs might remodel the phenotypes of the cells from ECs to EPCs by broadly changing their gene expression profile. Taken together the results indicate that OCT4 can remodel the phenotype of HUVECs from ECs to EPCs. To our knowledge, this study provides the first evidence indicating that OCT4 alone remodels the phenotype and promotes angiogenesis of HUVECs by changing the gene expression profile. Theoretically, these findings provide more insights on the role of OCT4 in keeping progenitor state of endothelial cells. Practically, the present study might provide an efficient way to generate adequate numbers of qualified EPCs for regenerative medicine.

Conclusions
===========

In the present study, we found that forced expression of mouse OCT4 in HUVECs remodels the phenotype of the cells from ECs to EPCs. This conclusion was supported by the following evidence: firstly forced expression of mouse OCT4 enhanced *in vitro*angiogenesis of the cells (EPCs have stronger *in vitro* angiogenesis ability than ECs); it up-regulated the expression of CD133, CD34, and VEGFR2 (they are characteristic molecular markers for human EPCs) and down-regulated CD31, VE-cadherin and vW-Factor (they are the molecular markers for mature ECs, but not expressed in their progenitor cells). Further by analyzing the cellular functions targeted by the mRNAs altered upon OCT4 expression we found that functions associated with stem cell maintenance were targeted by up-regulated mRNAs and cell differentiation functions were targeted by down-regulated mRNAs.
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![**Induced expression of OCT4 in HUVECs by DOX.**The mRNAs were analyzed by RT-QPCR and the amount of OCT4 mRNA was normalized to internal standard RPL13A mRNA. Relative fold was calculated based on the ratio of the normalized values of the cells incubated with (+DOX) to that without (-DOX) DOX. The data are expressed as Mean±SD, N=3, \*\* P\<0.01 versus that of -DOX cells.](ijmsv13p0386g001){#F1}

![**OCT4 enhanced angiogenesis of HUVECs.**The angiogenesis of the cells was evaluated by an *in vitro* angiogenesis assay kit, as described in the method section. A and B are representative microscopic photographs of uninduced and induced cells. C, D and E are statistically analyzed results. N=5, \*P\<0.05 and \*\*P\<0.01 versus that of -DOX cells.](ijmsv13p0386g002){#F2}

![**Scatter plot analysis of genes regulated by OCT4 in HUVECs.**A scatter chart for the normalized mRNA expression data, determined by using Microarray analysis, was made to show the general change of gene expression profile in HUVECs induced by DOX. +DOX and -DOX represent the mRNA values in the cells incubated with and without DOX, respectively. Each point on the scatter plot represents the expression level of an individual mRNA, as determined by units of fluorescence intensity. The default fold change value given is 2.0 (within the range of green lines). The points above the top and below the bottom green lines represent the mRNAs whose values changed more than 2 fold between two groups of cells. N=3.](ijmsv13p0386g003){#F3}

###### 

Primer sets used for RT-QPCR.

  Gene           Primer sets   Sequences                         GenBank
  -------------- ------------- --------------------------------- -----------
  hRPL13A        Forward       5\'-CGAGGTTGGCTGGAAGTACC-3\'      NM_012423
                 Reverse       5\'-CTTCTCGGCCTGTTTCCGTAG-3\'     
  mOCT4          Forward       5\'-CAGCCAGACCACCATCTGTC-3\'      NM_013633
                 Reverse       5\'-GTCTCCGATTTGCATATCTCCTG-3\'   
  hOCT4          Forward       5\'-GGGAGATTGATAACTGGTGTGTT-3\'   NM_203289
                 Reverse       5\'-GTGTATATCCCAGGGTGATCCTC-3\'   
  hKDR           Forward       5\'-GTGATCGGAAATGACACTGGAG-3\'    NM_002253
                 Reverse       5\'-CATGTTGGTCACTAACAGAAGCA-3\'   
  hCD34          Forward       5\'-CTACAACACCTAGTACCCTTGGA-3\'   NM_001773
                 Reverse       5\'-GGTGAACACTGTGCTGATTACA-3\'    
  hCD133         Forward       5\'-CCTCATGGTTGGAGTTGGAT-3\'      NM_006017
                 Reverse       5\'-TTCCACATTTGCACCAAAGA-3\'      
  hAVIL          Forward       5\'-ACAACGACCCTGGGATCATTG-3\'     NM_006576
                 Reverse       5\'-GTCGAGAGGATGACGTAGCAG-3\'     
  hS100A4        Forward       5\'-GATGAGCAACTTGGACAGCAA-3\'     NM_002961
                 Reverse       5\'-CTGGGCTGCTTATCTGGGAAG-3\'     
  hSLC12A3       Forward       5\'-CTCCACCAATGGCAAGGTCAA-3\'     NM_000339
                 Reverse       5\'-GGATGTCGTTAATGGGGTCCA-3\'     
  hS100P         Forward       5\'-AAGGATGCCGTGGATAAATTGC-3\'    NM_005980
                 Reverse       5\'-ACACGATGAACTCACTGAAGTC-3\'    
  hFOLR1         Forward       5\'-GCTCAGCGGATGACAACACA-3\'      NM_000802
                 Reverse       5\'-CCTGGCCCATGCAATCCTT-3\'       
  hIQCF1         Forward       5\'-CAGCCCCAAAAGACGAAGGAA-3\'     NM_152397
                 Reverse       5\'-GCTCCTAAGGACAAATGGGTTG-3\'    
  hCD31          Forward       5\'-AACAGTGTTGACATGAAGAGCC-3\'    NM_000442
                 Reverse       5\'-TGTAAAACAGCACGTCATCCTT-3\'    
  hVE-Cadherin   Forward       5\'-TTGGAACCAGATGCACATTGAT-3\'    NM_001795
                 Reverse       5\'-TCTTGCGACTCACGCTTGAC-3\'      
  hvW-Factor     Forward       5\'-CCGATGCAGCCTTTTCGGA-3\'       NM_000552
                 Reverse       5\'-TCCCCAAGATACACGGAGAGG-3\'     

###### 

Top 20 genes up-regulated by OCT4 in HUVECs.

       Genes      Fold Increase        Gene Name                                                                            GenBank
  ---- ---------- -------------------- ------------------------------------------------------------------------------------ -----------
  1    KRT10      97.0 ± 11.79^\*\*^   keratin 10 (epidermolytic hyperkeratosis; keratosis palmaris et plantaris)           NM_000421
  2    AVIL       85.2 ± 20.39^\*\*^   advillin                                                                             NM_006576
  3    KRT20      31.0 ± 6.12^\*\*^    keratin 20                                                                           NM_019010
  4    FMN1       30.5 ± 13.67^\*\*^   formin 1                                                                             BC103692
  5    EHF        29.9 ± 18.73^\*\*^   ets homologous factor                                                                AF124438
  6    PRND       27.2 ± 5.97^\*\*^    prion protein 2 (dublet)                                                             NM_012409
  7    OTOR       22.4 ± 11.89^\*\*^   otoraplin                                                                            NM_020157
  8    KDR        15.9 ± 1.57^\*\*^    kinase insert domain receptor (a type III receptor tyrosine kinase)                  NM_002253
  9    FLJ46906   15.5 ± 3.65^\*\*^    hypothetical gene supported by AK128874; BC071813                                    XM_928441
  10   GPNMB      14.2 ± 3.70^\*\*^    glycoprotein (transmembrane) nmb                                                     BC011595
  11   POU5F1     14.1 ± 0.82^\*\*^    POU domain, class 5, transcription factor 1                                          Z11898
  12   CD34       13.2 ± 1.82^\*\*^    CD34 molecule                                                                        BX538076
  13   FLJ37464   13.0 ± 1.55^\*\*^    hypothetical protein FLJ37464                                                        AK094783
  14   KCNMA1     11.7 ± 1.05^\*\*^    potassium large conductance calcium-activated channel, subfamily M, alpha member 1   NM_002247
  15   RNF36      11.4 ± 1.18^\*\*^    ring finger protein 36                                                               NM_080745
  16   CLDN11     11.0 ± 5.56^\*\*^    claudin 11 (oligodendrocyte transmembrane protein)                                   BC013577
  17   CD133      11.0 ± 2.86^\*\*^    prominin 1                                                                           NM_006017
  18   HS6ST3     11.0 ± 8.52^\*\*^    heparan sulfate 6-O-sulfotransferase 3                                               XM_931159
  19   CDH10      10.3 ± 2.35^\*\*^    cadherin 10, type 2 (T2-cadherin)                                                    NM_006727
  20   SUSD2      9.3 ± 1.83^\*\*^     sushi domain containing 2                                                            NM_019601

The mRNAs data (fluorescence) determined by Microarray assay were normalized through the Roche NimbleScan software. Relative fold values were calculated based on the ratio of the cells incubated with DOX to that without DOX. 20 most up-regulated genes are listed. Each value is the Mean ± SD from triplicate samples. \*\*p\<0.01, versus the -DOX cells.

###### 

Top 20 genes down-regulated by OCT4 in HUVECs.

  -------------------------------------------------------------------------------------------------------------------------------------------------------
       Genes       Fold Decrease       Gene Name                                                                                              GenBank
  ---- ----------- ------------------- ------------------------------------------------------------------------------------------------------ -----------
  1    LOC645009   0.04 ± 0.02^\*\*^   similar to GAGE-4 protein (G antigen 4)                                                                BC081536

  2    GAGE5       0.14 ± 0.15^\*\*^   G antigen 5                                                                                            NM_001475

  3    S100A4      0.14 ± 0.06^\*\*^   S100 calcium binding protein A4 (calcium protein, calvasculin, metastasin, murine placental homolog)   NM_002961

  4    SLC12A3     0.16 ± 0.01^\*\*^   solute carrier family 12 (sodium/chloride transporters), member 3                                      NM_000339

  5    S100P       0.08 ± 0.04^\*\*^   S100 calcium binding protein P                                                                         BC006819

  6    KRTHB1      0.05 ± 0.01^\*\*^   keratin, hair, basic, 1                                                                                NM_002281

  7    FRMD3       0.19 ± 0.20^\*\*^   FERM domain containing 3                                                                               AY137774

  8    WISP2       0.08 ± 0.04^\*\*^   WNT1 inducible signaling pathway protein 2                                                             BC058074

  9    GAGE8       0.10 ± 0.07^\*\*^   G antigen 8                                                                                            NM_012196

  10   FOLR1       0.11 ± 0.09^\*\*^   folate receptor 1 (adult)                                                                              NM_000802

  11   IQCF1       0.24 ± 0.26^\*\*^   IQ motif containing F1                                                                                 NM_152397

  12   LPAL2       0.10 ± 0.05^\*\*^   lipoprotein, Lp(a)-like 2                                                                              AK125910

  13   FOLR3       0.38 ± 0.44^\*\*^   folate receptor 3 (gamma)                                                                              U08470

  14   SLC16A6     0.17 ± 0.16^\*\*^   solute carrier family 16 (monocarboxylic acid transporters), member 6                                  NM_004694

  15   A2M         0.10 ± 0.05^\*\*^   alpha-2-macroglobulin                                                                                  NM_000014

  16   DKFZP686\   0.06 ± 0.01^\*\*^   hypothetical protein                                                                                   NM_014988
       A01247                                                                                                                                 

  17   SNCG        0.12 ± 0.07^\*\*^   synuclein, gamma (breast cancer-specific protein 1)                                                    NM_003087

  18   SVEP1       0.14 ± 0.10^\*\*^   sushi, von Willebrand factor type A, EGF and pentraxin domain containing 1                             XM_933024

  19   FAM46A      0.13 ± 0.10^\*\*^   family with sequence similarity 46, member A                                                           NM_017633

  20   GDA         0.13 ± 0.03^\*\*^   guanine deaminase                                                                                      NM_004293
  -------------------------------------------------------------------------------------------------------------------------------------------------------

The mRNAs data (fluorescence) determined by using Microarray assay were normalized through the Roche NimbleScan software. Relative fold expression was calculated based on the ratio of the cells incubated with DOX to that without DOX. 20 most down-regulated genes are listed. Each value is the Mean ± SD from triplicate samples. \*\*p\<0.01, versus the -DOX cells.

###### 

Validation of the mRNAs expression by RT-QPCR.

  mRNAs         Folds (+DOX/-DOX)   
  ------------- ------------------- -----------------
  AVIL          85.2 ± 20.39\*\*    12.2 ± 2.64\*\*
  OCT4          14.1 ± 0.82\*\*     26.4 ± 1.98\*\*
  KDR           15.8 ± 1.57\*\*     7.9 ± 2.20\*\*
  CD34          13.2 ± 1.82\*\*     10.8 ± 2.22\*\*
  CD133         11.0 ± 2.86\*\*     8.1 ± 1.47\*\*
  S100A4        0.14 ± 0.06\*\*     0.14 ± 0.25\*\*
  SLC12A3       0.16 ± 0.01\*\*     0.23 ± 0.11\*\*
  S100P         0.08 ± 0.04\*\*     0.08 ± 0.04\*\*
  FOLR1         0.11 ± 0.09\*\*     0.11 ± 0.20\*\*
  IQCF1         0.24 ± 0.26\*\*     0.12 ± 0.06\*\*
  CD31          0.36 ± 0.24\*\*     0.12 ± 0.02\*\*
  VE-Cadherin   0.15 ± 0.05\*\*     0.27 ± 0.05\*\*
  vW-Factor     0.60 ± 0.17\*\*     0.37 ± 0.19\*\*

The mRNAs determined by Microarray assay and RT-QPCR were normalized through the Roche NimbleScan software and by the internal standard RPL13A mRNA, respectively. Relative fold values in expression were calculated based on the ratio of the cells incubated in the presence (+DOX ) to that of the cells in the absence (-DOX ) of DOX. Each value is the Mean ± SD from triplicate samples. \*\*p\<0.01, versus the -DOX cells.

###### 

Molecular functions of genes regulated by OCT4.

  Up-regulated by OCT4                        *p*-value\*   FDR\#
  ------------------------------------------- ------------- -------------
  immune response                             1.3379E-06    0.00595899
  apoptotic signaling pathway                 7.4837E-06    0.007612657
  defense response                            2.0037E-05    0.044623077
  response to stress                          2.2132E-05    0.010952796
  positive regulation of cellular process     3.7134E-05    0.015073193
  multi-organism process                      4.0214E-05    0.198188031
  response to biotic stimulus                 4.6818E-05    0.443289936
  stem cell maintenance                       5.0928E-05    0.443289936
  multicellular organismal signaling          5.7531E-05    0.458326667
  positive regulation of biological process   6.3142E-05    0.015624031
  Down-regulated by OCT4                                    
  response to stimulus                        7.1105E-11    1.5835E-07
  cell differentiation                        2.9436E-09    4.15823E-06
  system development                          4.2726E-09    4.15823E-06
  multicellular organismal development        5.6016E-09    4.15823E-06
  anatomical structure development            6.1858E-08    2.41044E-05
  cell adhesion                               2.8368E-07    8.5696E-05
  biological adhesion                         3.1936E-07    8.89007E-05
  cell-cell signaling                         5.425E-07     0.000142136
  locomotion                                  3.9781E-06    0.000610987
  tissue development                          1.6513E-05    0.002228712

Gene Ontology (GO) analysis was carried out on the differentially expressed mRNAs determined by Microarray assay to explore their molecular functions. *p*-value\* stands for the significance testing value of the GO item and FDR\# stands for the false discovery rate of the GO item.
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